Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Takeda
Takeda
Activities:
Regulatory
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Manufacturing
Takeda's NDA for metastatic colorectal cancer treatment
The FDA has granted priority review of the New Drug Application for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors
Finance
Takeda Pharmaceutical to acquire GammaDelta Therapeutics
Abingworth was the founding investor in GammaDelta and provided initial seed funding as part of the company’s creation in 2016
Finance
Takeda to evaluate Aptamer Group reagents for drug development
Based on oligonucleotide molecules, Optimers (which the company describes as optimised aptamer reagents) can bind specifically to a target molecule to act as an antibody alternative
Finance
Adaptate Biotherapeutics raises $18 m in Series A2 funding
The financing will also support the company’s expansion, including further recruitment and increased laboratory and office space
Finance
Novadiscovery enters clinical simulation collaboration with Takeda
This agreement builds on an existing relationship between the companies that began in 2017
Manufacturing
Future thoughts about pharmaceutical manufacturing
COPA-DATA's Giuseppe Menin and his colleagues from an ISPE working group discuss shifting from a systems to a service-oriented architecture
Manufacturing
Takeda opens cell therapy manufacturing facility in Boston
The next-generation cell therapies will initially focuse on oncology with potential to expand into other therapeutic areas
Subscribe now